Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
57°
Clear
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Merck & Co
(NY:
MRK
)
118.45
+0.99 (+0.84%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Merck & Co
< Previous
1
2
...
12
13
14
15
16
17
18
19
Next >
New Research for KEYTRUDA® (pembrolizumab) at Society for Melanoma Research (SMR) 2021 Congress Reinforces Merck’s Commitment to Patients With Melanoma Across Stages of Disease
October 31, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces Withdrawal and Refiling under the Hart-Scott-Rodino Act and Extension of Tender Offer to Acquire Acceleron Pharma Inc.
October 29, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces Third-Quarter 2021 Financial Results
October 28, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck for Mothers: Helping End Maternal Mortality
September 29, 2021
SOURCE: Merck & Co., Inc.
Via
3BL Media
Topics
Death
Exposures
Death
Merck Presents New Data from Ongoing Phase 2b Clinical Trial Evaluating Efficacy and Safety of Investigational Islatravir in Combination With Doravirine Through 144 Weeks for HIV-1 Treatment at EACS 2021
October 27, 2021
From
Merck & Co., Inc.
Via
Business Wire
The Medicines Patent Pool (MPP) and Merck Enter Into License Agreement for Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, to Increase Broad Access in Low- and Middle-Income Countries
October 27, 2021
From
Merck & Co., Inc.
Via
Business Wire
Gilead and Merck Initiate Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Lenacapavir and Investigational Islatravir for HIV-1 Treatment in Virologically Suppressed Adults
October 26, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Merck Announces Positive Top-Line Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily Oral Fixed Dose Combination of Doravirine/Islatravir for the Treatment of People with HIV-1 Infection
October 25, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck and Ridgeback Announce Initiation of a Rolling Review by the European Medicines Agency for Molnupiravir, an Investigational Oral Antiviral Medicine, for the Treatment of COVID-19 in Adults
October 25, 2021
From
Merck & Co., Inc.
Via
Business Wire
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Treatment for Certain Patients With Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer (TNBC)
October 22, 2021
From
Merck & Co., Inc.
Via
Business Wire
CDC ACIP Unanimously Votes to Provisionally Recommend Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) in Series with PNEUMOVAX ® 23 (Pneumococcal Vaccine Polyvalent) as an Option for Pneumococcal Vaccination in Appropriate Adults
October 20, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck Issues Voluntary Nationwide Recall of CUBICIN® (daptomycin for injection) 500 mg, Lot 934778, Due to Presence of Particulate Matter Identified as Glass Particles
October 19, 2021
From
Merck & Co., Inc.
Via
Business Wire
Is This The Most Exciting Medical Breakthrough Of The Decade
October 19, 2021
FN Media Group Presents Oilprice.com Market Commentary London – October 19, 2021 – According to Google’s Health boss David Feinberg… over one billion people a day search Google for health concerns....
Via
FinancialNewsMedia
6 Global Trends Critical to Patients During the COVID-19 Pandemic
October 18, 2021
SOURCE: Merck & Co., Inc.
Via
3BL Media
Exposures
COVID-19
Merck and Eisai Receive Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Two Different Types of Cancer
October 15, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck Receives Positive CHMP Opinion for VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) in Individuals 18 Years of Age and Older
October 15, 2021
From
Merck & Co., Inc.
Via
Business Wire
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Bevacizumab, as Treatment for Patients With Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS ≥1)
October 13, 2021
From
Merck & Co., Inc.
Via
Business Wire
Humans, Animals and the Environment - Our Health Is All Connected
October 13, 2021
SOURCE: Merck & Co., Inc.
Via
3BL Media
Topics
Climate Change
Exposures
Climate
U.S. Is Dominating Psychedelic Drugs Market Due To Growing Acceptance For Treating Depression & Rise In Product Approvals
October 12, 2021
Palm Beach, FL –October 12, 2021 – FinancialNewsMedia.com News Commentary – After being relegated to the margins of sincere scientific examination for about the last several decades, growing...
Via
FinancialNewsMedia
Merck Begins Tender Offer to Acquire Acceleron Pharma Inc.
October 12, 2021
From
Merck & Co., Inc.
Via
Business Wire
Rapid Advancements of Innovative Antiviral – COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market
October 11, 2021
Palm Beach, FL –October 11, 2021 – FinancialNewsMedia.com News Commentary – With the arrival of the COVID-19 virus, the antivirals market had all eyes watching the ongoing frenetic rush to find a cure...
Via
FinancialNewsMedia
Exposures
COVID-19
Merck and Ridgeback Announce Submission of Emergency Use Authorization Application to the U.S. FDA for Molnupiravir, an Investigational Oral Antiviral Medicine, for the Treatment of Mild-to-Moderate COVID-19 in At Risk Adults
October 11, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck and Emmy-Nominated Actress Yvonne Orji Unveil Uncovering TNBC, Highlighting the Challenges Faced by Black Women Diagnosed with Triple-Negative Breast Cancer
October 05, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck and Ridgeback’s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study
October 01, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck to Acquire Acceleron Pharma Inc.
September 30, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces Appointment of Thomas H. Glocer as Independent Lead Director
September 29, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck to Hold Third-Quarter 2021 Sales and Earnings Conference Call on October 28
September 28, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces KEYTRUDA® (pembrolizumab) Met Primary Endpoint of Overall Survival (OS) in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib
September 27, 2021
From
Merck & Co., Inc.
Via
Business Wire
LYNPARZA® (olaparib) in Combination With Abiraterone Significantly Delayed Disease Progression in Patients Regardless of Biomarker Status in PROpel Phase 3 Trial in First-Line Metastatic Castration-Resistant Prostate Cancer (mCRPC)
September 24, 2021
From
Merck & Co., Inc.
Via
Business Wire
Building Sustainable Value for Our Business and Society
September 22, 2021
SOURCE: Merck & Co., Inc.
Via
3BL Media
Exposures
COVID-19
< Previous
1
2
...
12
13
14
15
16
17
18
19
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.